Literature DB >> 3207646

Endometrioid carcinoma of the ovary: a retrospective study.

J Tidy1, W P Mason.   

Abstract

Thirty-nine women with endometrioid carcinoma of the ovary were studied for factors relating to their presentation, treatment and survival. Nine of the women (23%) had a concomitant adenocarcinoma of the endometrium at the time of presentation. There were no significant differences in age at presentation or menopausal status between the two groups. The actuarial 5-year survival for women with endometrioid carcinoma of the ovary alone was 43%, 95% confidence interval (CI) 24% to 62% (stage I 80%, CI 45% to 100%, stage II 62%, CI 27% to 97%, and stage III 21%, CI 0% to 42%). The 5-year survival for women with concomitant endometrial tumours was 62.5% (CI 28.5% to 96.5%). The difference in the overall survival rate between the two groups was not significant.

Entities:  

Mesh:

Year:  1988        PMID: 3207646     DOI: 10.1111/j.1471-0528.1988.tb06795.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

1.  Synchronous bilateral endometrioid ovarian cancer and uterine adenocarcinoma in a young woman.

Authors:  Mansour Al-Moundhri; Mariam Mathew; Andrzej Krolikowski
Journal:  J Sci Res Med Sci       Date:  2001-04

Review 2.  Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study.

Authors:  J Rabczyński; P Ziółkowski
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

3.  Concomitant endometrioid carcinoma of the ovary and endometrial carcinoma of the uterus associated with adenocarcinoma in situ of the cervix.

Authors:  M Parker; R Wallace; D Allen
Journal:  Ulster Med J       Date:  1989-10

4.  Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012.

Authors:  Se Ik Kim; Myong Cheol Lim; Jiwon Lim; Young Joo Won; Sang Soo Seo; Sokbom Kang; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.